William J Honnen
Overview
Explore the profile of William J Honnen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
635
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Magni R, Rruga F, Alsaab F, Sharif S, Howard M, Espina V, et al.
Sci Rep
. 2021 Sep;
11(1):19546.
PMID: 34580341
No abstract available.
2.
Horton D, Barrett E, Roy J, Gennaro M, Andrews T, Greenberg P, et al.
J Infect Dis
. 2021 Aug;
224(8):1345-1356.
PMID: 34387310
Background: We studied risk factors, antibodies, and symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a diverse, ambulatory population. Methods: A prospective cohort (n = 831) previously...
3.
Magni R, Rruga F, Alsaab F, Sharif S, Howard M, Espina V, et al.
Sci Rep
. 2020 Aug;
10(1):13944.
PMID: 32811861
An accurate urine test for diverse populations with active tuberculosis could be transformative for preventing TB deaths. Urinary liporabinomannan (LAM) testing has been previously restricted to HIV co-infected TB patients....
4.
Sigal G, Pinter A, Lowary T, Kawasaki M, Li A, Mathew A, et al.
J Clin Microbiol
. 2018 Sep;
56(12).
PMID: 30257899
The only currently commercialized point-of-care assay for tuberculosis (TB) that measures lipoarabinomannan (LAM) in urine (Alere LF-LAM) has insufficient sensitivity. We evaluated the potential of 100 novel monoclonal antibody pairs...
5.
Amin A, De P, Spencer J, Brennan P, Daum J, Andre B, et al.
Tuberculosis (Edinb)
. 2018 Jul;
111:178-187.
PMID: 30029905
TB diagnosis and treatment monitoring in resource limited regions rely heavily on serial sputum smear microscopy and bacterial culture. These microbiological methods are time-consuming, expensive and lack adequate sensitivity. The...
6.
Krachmarov C, Lai Z, Honnen W, Salomon A, Gorny M, Zolla-Pazner S, et al.
J Virol
. 2011 Aug;
85(20):10730-40.
PMID: 21835798
A series of potently neutralizing monoclonal antibodies (MAbs) that target quaternary epitopes on the native Env trimer have recently been described. A common feature shared by these antibodies is the...
7.
Moore P, Gray E, Sheward D, Madiga M, Ranchobe N, Lai Z, et al.
J Virol
. 2011 Jan;
85(7):3128-41.
PMID: 21270156
The targets of broadly cross-neutralizing (BCN) antibodies are of great interest in the HIV vaccine field. We have identified a subtype C HIV-1-superinfected individual, CAP256, with high-level BCN activity, and...
8.
Pinter A, Honnen W, DAgostino P, Gorny M, Zolla-Pazner S, Kayman S
J Virol
. 2005 May;
79(11):6909-17.
PMID: 15890930
Monoclonal antibodies (MAbs) directed against epitopes in the V2 domain of human immunodeficiency virus type 1 gp120 often possess neutralizing activity, but these generally are highly type specific, neutralize only...
9.
Krachmarov C, Pinter A, Honnen W, Gorny M, Nyambi P, Zolla-Pazner S, et al.
J Virol
. 2004 Dec;
79(2):780-90.
PMID: 15613306
Sera from human immunodeficiency virus type 1 (HIV-1)-infected North American patients recognized a fusion protein expressing a V3 loop from a clade B primary isolate virus (JR-CSF) but not from...
10.
Pinter A, Honnen W, He Y, Gorny M, Zolla-Pazner S, Kayman S
J Virol
. 2004 Apr;
78(10):5205-15.
PMID: 15113902
A major problem hampering the development of an effective vaccine against human immunodeficiency virus type 1 (HIV-1) is the resistance of many primary viral isolates to antibody-mediated neutralization. To identify...